Immunovant (IMVT) Cash from Investing Activities (2019 - 2026)
Immunovant's (IMVT) quarterly Cash from Investing Activities came in at -$8000.0 in Q1 2026, up 96.02% YoY from -$4081.2 in Q1 2025, and up 96.02% on a QoQ basis from -$201000.0 in Q1 2025.
Powered by 
Analysis
Immunovant (IMVT) Cash from Investing Activities (2019 - 2026) Analysis & Trends
Immunovant (IMVT) has 8 years of Cash from Investing Activities data on file, last reported at -$8000.0 in Q1 2026.
- Quarterly Cash from Investing Activities rose 96.02% year-over-year to -$8000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8000.0 (up 98.95% YoY) and the FY2026 annual result came in at -$8000.0, up 98.95% from the prior year.
- Cash from Investing Activities grew to -$8000.0 in Q1 2026, from -$201000.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of -$8000.0 in Q1 2026 to a low of -$201000.0 in Q1 2025.
- A 5-year average of -$103000.0 and a median of -$108000.0 in 2022 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2024 — Cash from Investing Activities slumped 476.92% — and 2026, when it soared 96.02%.
- Tracing IMVT's Cash from Investing Activities over 5 years: stood at -$98000.0 in 2022, then plunged by 33.67% to -$131000.0 in 2023, then slumped by 37.4% to -$180000.0 in 2024, then fell by 11.67% to -$201000.0 in 2025, then soared by 96.02% to -$8000.0 in 2026.
- The last three Cash from Investing Activities figures came in at -$8000.0 (Q1 2026), -$201000.0 (Q1 2025), and -$180000.0 (Q4 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 329.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -1.66 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -49.35 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -229.72 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Immunovant | 8.07 Bn | 8.07 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -8,000.00 |
| Mar 31, 2025 | -201,000.00 |
| Dec 31, 2024 | -180,000.00 |
| Sep 30, 2024 | -196,000.00 |
| Jun 30, 2024 | -182,000.00 |
| Mar 31, 2024 | -150,000.00 |
| Dec 31, 2023 | -131,000.00 |
| Sep 30, 2023 | -34,000.00 |
| Jun 30, 2023 | -45,000.00 |
| Mar 31, 2023 | -26,000.00 |
| Dec 31, 2022 | -98,000.00 |
| Sep 30, 2022 | -31,000.00 |
| Jun 30, 2022 | -42,000.00 |
| Mar 31, 2022 | -118,000.00 |
| Dec 31, 2021 | -74,000.00 |
| Sep 30, 2021 | -44,000.00 |
| Jun 30, 2021 | -18,000.00 |
| Mar 31, 2021 | -95,000.00 |
| Dec 31, 2020 | -29,000.00 |
| Sep 30, 2020 | -39,000.00 |